Nektar Therapeutics (NASDAQ:NKTR) disclosed that its Chief R&D Officer, Jonathan Zalevsky, disposed of 192 shares of the company's common stock on November 17, 2026. The shares were sold at prices ranging from $35.57 to $36.31, with a weighted average sale price of $35.85, resulting in total proceeds of $6,883.
The filing indicates that the transaction was not a discretionary trade by Zalevsky. Instead, the shares were sold to cover required tax withholding obligations associated with the vesting of restricted stock units. After the sale, Zalevsky directly holds 9,378 shares of Nektar Therapeutics common stock.
The disclosure arrives at a challenging moment for the company's stock. NKTR shares are currently trading at $32.54, only marginally above their 52-week low of $32.51. Over the past week, the stock has declined 12.7%, and it has fallen 53% over the last six months, according to InvestingPro data.
InvestingPro Tips highlight that the company is quickly burning through cash and that analysts do not anticipate profitability this year. These are two of 12 key insights available to subscribers. For deeper analysis, investors can access NKTR's comprehensive Pro Research Report, part of the platform's coverage of over 1,400 US equities.
In other recent news, Nektar Therapeutics reported its third-quarter financial results, revealing a narrower-than-expected loss. The company posted an adjusted earnings per share loss of $1.63, surpassing analysts' expectations of a $2.08 loss. However, Nektar's revenue of $9.39 million fell short of the anticipated $10.31 million.
As of September 30, 2026, the company held $952.9 million in cash and investments, which is expected to sustain operations into the third quarter of 2028. This cash reserve is intended to support Nektar through the Phase 3 ZENITH AD trials for atopic dermatitis. Despite the earnings beat, investors seemed more concerned with the revenue miss and the extended timeline to commercialization.
Additionally, the company has advanced its REZPEG treatment into Phase III studies for atopic dermatitis and alopecia areata. These developments are crucial for Nektar as it continues to focus on its pipeline progress over immediate sales.
The insider sale, while small in dollar terms, provides a window into the routine financial planning of a key executive at a company navigating a critical period. The stock's proximity to its 52-week low and the substantial decline over the past six months underscore the pressures facing Nektar as it balances pipeline advancement with financial sustainability.